Assessment of Gastrointestinal Adverse Effects during the First Six Months of "Biktarvy" Antiretroviral Therapy: Age-Related Patterns and Their Relation with Changes of 5 kg Weight Loss/Gain in the Initial Treatment Period

• Published in: Diseases Vol. 12; no. 1; p. 3
• Main Authors: Suba, Madalina-Ianca, Abu-Awwad, Simona-Alina, Rosca, Ovidiu, Turaiche, Mirela-Mădălina, Hogea, Bogdan, Abu-Awwad, Ahmed, Nitu, Razvan, Lazureanu, Voichita Elena
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 01.01.2024
• Subjects: Adverse and side effects; Age; Age factors in disease; Antiretroviral therapy; bictegravir; BIKTARVY; Causes of; CD4 antigen; Complications and side effects; Data collection; Diarrhea; Dosage and administration; Drug therapy; Drugs; Electronic medical records; Emtricitabine; Health aspects; Highly active antiretroviral therapy; HIV; HIV infection; Human immunodeficiency virus; Medical records; Patients; Quality of life; Side effects; Statistical analysis; Tenofovir; tenofovir alafenamide; Weight; Weight loss; Romania; bictegravir; emtricitabine; HIV; age-related patterns; treatment outcomes; antiretroviral therapy; weight loss; BIKTARVY; gastrointestinal adverse effects; tenofovir alafenamide
• ISSN: 2079-9721; 2079-9721
• DOI: 10.3390/diseases12010003

The battle against HIV has led to the development of antiretroviral therapy (ART), including BIKTARVY , which combines three potent agents. However, concerns about gastrointestinal side effects during the early phases of treatment have emerged, potentially impacting patient adherence and outcomes. This retrospective cohort study, conducted over four years in Romania, examined 222 patients initiated on BIKTARVY therapy. Data were collected from electronic medical records, and stringent inclusion and exclusion criteria were applied to ensure data accuracy and relevance. Statistical analysis was performed to assess age-related patterns in gastrointestinal symptoms and their relation with significant weight loss. This study revealed significant differences in the prevalence of gastrointestinal symptoms between age groups, with older patients experiencing more symptoms. Notably, diarrhea did not exhibit a statistically significant age-related difference. Furthermore, weight loss exceeding 5 kg was more common in older patients. Of the patients who continued BIKTARVY therapy, 84.9% showed an increase in CD4 cell counts, and most expressed satisfaction with treatment. Understanding age-related patterns and gastrointestinal side effects of BIKTARVY is crucial for optimizing HIV patient care. Future research should aim to corroborate and expand upon these findings, potentially leading to improved therapeutic approaches in the ongoing fight against HIV.